Pharmaceutical R&D Pipeline News
Therapy Analysis
Influenza, a persistant threat
Nobel laureate Joshua Lederberg once commented that “the single biggest threat to man’s continued dominance on the planet is the virus”. Throughout recent history, few viruses have had such a global impact as influenza. The 20th century alone saw several major pandemic outbreaks, each with significant death tolls. Perhaps most worryingly, recent years have seen a resurgence of more virulent strains of influenza, once again highlighting the threat posed by this virus.
Influenza, more commonly known as the ‘flu, is an infectious respiratory disease caused by single-stranded RNA viruses belonging to the Orthomyxoviridae family. Typically transmitted through saliva and nasal secretions by coughing and sneezing, influenza viruses cause a variety of symptoms including headache, cough, fever, sore throat, myalgia and general malaise. The typical epidemiological pattern of influenza is of seasonal epidemics. In this, its commonest form, influenza has consistently been, and remains, the scourge of the winter months. It invariably results in hundreds of thousands of ‘flu-related deaths in vulnerable populations, and remains a persistent problem for health authorities throughout the world.
Latest R&D News
Our news is available via RSS feed. If you are new to RSS news read about how to use it.
-
First approval for Ilaris
Fri, 19 Jun 2009 12:13:50 GMT
Novartis has received its first market approval of Ilaris (canakinumab) in the US. Ilaris is a human monoclonal antibody directed against interleukin-1beta... more -
US approval for macular oedema implant
Thu, 18 Jun 2009 16:19:32 GMT
The US FDA has approved Allergan's Ozurdex (dexamethasone) injectable biodegradable implant, for the treatment of macular oedema following branch retinal vein occlusion or central retinal vein occlusion... more -
Breathing new life into inhaled insulin?
Thu, 11 Jun 2009 14:34:40 GMT
Mannkind Corporation has presented new data on its inhaled insulin propect, Afresa, indicating that it may be comparable to the injectable standard of care... more -
Merck discontinues rolofylline following Phase III trial results
Wed, 10 Jun 2009 14:38:07 GMT
Rolofylline (MK-7418) has failed to meet its primary and secondary efficacy endpoints in two Phase III trials (PROTECT-1 and PROTECT-2) across a total of 2,034 patients for the treatment of acute heart failure... more
Mergers, Acquistions & Joint Ventures
- Clinical Data has acquired Avalon.
- Glycotope has acquired Nemod Biotherapeutics.
- Modigene has changed its name and will henceforth be known as Protor Biotech.
New Drug Targets
Newly identified drug protein targets.








